Publications by authors named "Tomoko Akita"
Article Synopsis
- The study analyzed the effects of high-dose chemoradiotherapy combined with respiratory motion management on patients with esophageal squamous cell carcinoma (ESCC) between 2012 and 2018.
- Out of 35 patients, the treatment showed a high overall response rate of 94.3%, with a median follow-up of 43 months, but significant survival differences were noted based on the presence of esophageal fistulas.
- While the treatment was generally effective, it also resulted in major toxicities, especially decreased blood cell counts, indicating the need for careful consideration of risks like esophageal fistulas in future candidates.
Background: The purpose of this study was to compare the dosimetric characteristics of five different treatment planning techniques for locally advanced non-small cell lung cancer (LA-NSCLC) with sequential plan changes.
Methods: A total of 13 stage III NSCLC patients were enrolled in this study. These patients had both computed tomography (CT) images for initial and boost treatment plans.
Article Synopsis
- Surgery is the standard treatment for stage I non-small cell lung cancer (NSCLC), but there's limited evidence on whether it's better than stereotactic body radiotherapy (SBRT) for survival.
- A study analyzed data from 399 operable stage I NSCLC patients in Japan to assess the real-world outcomes of SBRT, noting a median follow-up of 38 months and various survival rates based on cancer subtype and patient characteristics.
- Results showed an overall 3-year survival rate of 77%, with female patients doing better than males, highlighting SBRT's potential as a viable treatment option for older patients with stage I NSCLC and guiding shared decision-making in their care.
Background And Purpose: We aimed to validate the usefulness of prescriptions based on gross tumor volume for stereotactic body radiotherapy for small peripheral lung tumors.
Materials And Methods: Radiotherapy treatment planning data of 50 patients with small peripheral lung tumors (adenocarcinoma: 24, squamous cell carcinoma: 10, other: 1, unknown: 15) receiving breath-hold computed tomography-guided stereotactic body radiotherapy at our institution during 2013-2016 were analyzed. For each case, 3 dose prescription methods were applied: one based on 95% (PTVD) of the planning target volume, one based on 50% of the gross tumor volume (GTVD), and one based on 98% (GTVD) of the gross tumor volume.